US approves novel remedy for hayfever, pollen allergies (Update)

April 2, 2014

US regulators on Wednesday approved a French-made remedy for alleviating symptoms of hayfever and certain allergies to grass pollen.

The tablet, called Oralair, dissolves under the tongue and must be taken daily for four months prior to the start of the grass pollen season, and then continued throughout the season.

Pre-approval trials on 2,500 people found that those who took the remedy experienced a 16 to 30 percent reduction in symptoms, which can include sneezing, runny nose, and itchy, watery eyes.

Manufactured by Stallergenes S.A. of Antony, France, the tablet contains freeze-dried extracts from the pollens of five grasses, including Kentucky Blue Grass, Orchard, Perennial Rye, Sweet Vernal and Timothy.

It is the first US Food and Drug Administration-approved allergen extract that can be dissolved under the tongue, the agency said in a statement.

"The approval of Oralair provides an alternative to allergy shots that must be given in a health care provider's office," said Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research.

"While there is no cure for grass pollen allergies, they can be managed through treatment and avoiding exposure to the pollen."

These allergies affect some 30 million people in the United States and more than 500 million worldwide, according to the FDA.

Explore further: Canada approves Merck grass allergy immunotherapy

Related Stories

Canada approves Merck grass allergy immunotherapy

February 3, 2014
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

FDA panel considers first pill for ragweed allergy

January 28, 2014
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.

Spring is here, but so are allergies

March 21, 2014
Spring has finally arrived in Cincinnati, but soon to follow will be the coughing, sneezing and wheezing that comes with allergies, hay fever and asthma—three warm weather killjoys most could do without.

Get ready for spring - hay fever worse in spring than summer

December 21, 2011
Hay fever (runny nose, sneezing, itchy eyes) is caused by an allergy to pollen, and most commonly to grass pollen. These tiny grains bring misery to sufferers through spring and summer and pollen levels are often included ...

Recommended for you

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.